{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:05:42Z","timestamp":1780524342534,"version":"3.54.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"32","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.vaccine.2022.04.085","type":"journal-article","created":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T03:50:54Z","timestamp":1654919454000},"page":"4453-4463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9712-8080","authenticated-orcid":false,"given":"Christine S.","family":"Rollier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Dold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Blackwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Linder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Silva-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Clutterbuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Harbinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"O'Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Snape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.04.085_b0005","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1517\/14712598.2015.983897","article-title":"The capsular group B meningococcal vaccine, 4CMenB : clinical experience and potential efficacy","volume":"15","author":"Rollier","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"39","key":"10.1016\/j.vaccine.2022.04.085_b0010","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.1016\/j.vaccine.2015.06.103","article-title":"Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study","volume":"33","author":"Perrett","year":"2015","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.04.085_b0015","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1542\/peds.2014-4015","article-title":"First use of a serogroup B meningococcal vaccine in the US in response to a university outbreak","volume":"135","author":"McNamara","year":"2015","journal-title":"Pediatrics"},{"issue":"36","key":"10.1016\/j.vaccine.2022.04.085_b0020","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1016\/j.vaccine.2015.06.011","article-title":"Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults","volume":"33","author":"Nolan","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.04.085_b0025","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1128\/CVI.00669-14","article-title":"A large portion of meningococcal antigen typing system-negative meningococcal strains from spain is killed by sera from adolescents and infants immunized with 4CMenB: TABLE 1","volume":"22","author":"Abad","year":"2015","journal-title":"Clin Vaccine Immunol"},{"issue":"10061","key":"10.1016\/j.vaccine.2022.04.085_b0030","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study","volume":"388","author":"Parikh","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.04.085_b0035","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"15","key":"10.1016\/j.vaccine.2022.04.085_b0040","doi-asserted-by":"crossref","first-page":"E715","DOI":"10.1503\/cmaj.130257","article-title":"Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose","volume":"185","author":"Snape","year":"2013","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2022.04.085_b0045","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/INF.0b013e31829cfff2","article-title":"Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial","volume":"32","author":"Snape","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.085_b0050","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-019-3494-1","article-title":"The effect of a single 4CMenB vaccine booster in young people more than ten years after infant immunisation: protocol of an exploratory immunogenicity study","volume":"20","author":"Davis","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.vaccine.2022.04.085_b0055","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2022.04.085_b0060","first-page":"970","article-title":"Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44\/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine","volume":"12","author":"Borrow","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"issue":"24","key":"10.1016\/j.vaccine.2022.04.085_b0065","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","article-title":"Neisseria meningitidis group B correlates of protection and assay standardization-International Meeting Report Emory University, Atlanta, Georgia, United States, 16\u201317 March 2005","volume":"24","author":"Borrow","year":"2006","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.085_b0070","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2352-4642(18)30103-2","article-title":"Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: a prospective surveillance study","volume":"2","author":"Bryan","year":"2018","journal-title":"Lancet Child Adolesc Heal"},{"issue":"9816","key":"10.1016\/j.vaccine.2022.04.085_b0075","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2022.04.085_b0080","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2018.12.059","article-title":"Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine","volume":"37","author":"Nolan","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.04.085_b0085","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1080\/21645515.2021.1904758","article-title":"High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007\u20132011: Concordant predictions between MATS and genetic MATS","volume":"17","author":"Tozer","year":"2021","journal-title":"Hum Vacc Immunother"},{"key":"10.1016\/j.vaccine.2022.04.085_b0090","doi-asserted-by":"crossref","unstructured":"Parikh, S. R. et al. Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007\u201308 and 2014\u201315: a qualitative and quantitative assessment. The Lancet Infectious Diseases 2017;17. <www.thelancet.com\/infection>.","DOI":"10.1016\/S1473-3099(17)30170-6"},{"key":"10.1016\/j.vaccine.2022.04.085_b0095","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"7659","key":"10.1016\/j.vaccine.2022.04.085_b0100","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1136\/bmj.39563.545255.AE","article-title":"Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: Observational study","volume":"336","author":"Snape","year":"2008","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.vaccine.2022.04.085_b0105","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nri2494","article-title":"Maintaining protection against invasive bacteria with protein- polysaccharide conjugate vaccines","volume":"9","author":"Pollard","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"28","key":"10.1016\/j.vaccine.2022.04.085_b0110","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.vaccine.2017.05.023","article-title":"Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial","volume":"35","author":"Martin\u00f3n-Torres","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.04.085_b0115","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.4049\/jimmunol.1200451","article-title":"B cell memory to a serogroup C meningococcal conjugate vaccine in childhood and response to booster: little association with serum IgG antibody","volume":"189","author":"Perrett","year":"2012","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.vaccine.2022.04.085_b0120","doi-asserted-by":"crossref","first-page":"e23497","DOI":"10.1371\/journal.pone.0023497","article-title":"Age-related immunity to meningococcal serogroup C vaccination: An increase in the persistence of IgG2 correlates with a decrease in the avidity of IgG","volume":"6","author":"de Voer","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2022.04.085_b0125","doi-asserted-by":"crossref","unstructured":"Knuf M, Baine Y, Bianco V, Boutriau D, Miller JM. Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children. 2012;8:866\u2013872. http:\/\/dx.doi.org\/10.4161\/hv.20229.","DOI":"10.4161\/hv.20229"},{"issue":"29","key":"10.1016\/j.vaccine.2022.04.085_b0130","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1016\/j.vaccine.2015.05.027","article-title":"Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers","volume":"33","author":"Findlow","year":"2015","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.04.085_b0135","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1080\/21645515.2017.1381810","article-title":"Impact of meningococcal group B OMV vaccines, beyond their brief","volume":"14","author":"Petousis-Harris","year":"2018","journal-title":"Human Vacc Immunother"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.085_b0140","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4161\/hv.24129","article-title":"Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV) Lessons from past programs and implications for the future","volume":"9","author":"Holst","year":"2013","journal-title":"Human Vacc Immunother"},{"key":"10.1016\/j.vaccine.2022.04.085_b0145","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1093\/cid\/cix519","article-title":"Serum Bactericidal antibody responses of students immunized with a meningococcal serogroup B vaccine in response to an outbreak on a university campus","volume":"65","author":"Lujan","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.04.085_b0150","doi-asserted-by":"crossref","unstructured":"Pinto MV, et al. Immunogenicity and reactogenicity of a reduced schedule of a 4-component capsular group b meningococcal vaccine: A randomized controlled trial in infants. Open Forum Infect Dis 2020;7.","DOI":"10.1093\/ofid\/ofaa143"},{"issue":"43","key":"10.1016\/j.vaccine.2022.04.085_b0155","doi-asserted-by":"crossref","first-page":"7387","DOI":"10.1016\/j.vaccine.2011.07.072","article-title":"Human antibody and memory B and T-cell responses after primary and booster immunisation against Neisseria meningitidis B","volume":"29","author":"Cruz","year":"2011","journal-title":"Vaccine"},{"issue":"32","key":"10.1016\/j.vaccine.2022.04.085_b0160","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1016\/j.vaccine.2017.05.065","article-title":"Durability of immunogenicity and strain coverage of MenBvac, a meningococcal vaccine based on outer membrane vesicles: Lessons of the Normandy campaign","volume":"35","author":"Sevestre","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.04.085_b0165","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.1097\/INF.0000000000000897","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatr Infect Dis J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:15:54Z","timestamp":1759403754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22005394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":33,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0264410X22005394"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.085","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}